Literature DB >> 3714531

Proglumide fails to increase food intake after an ingested preload.

L H Schneider, J Gibbs, G P Smith.   

Abstract

Proglumide, a selective antagonist of exogenous cholecystokinin in vitro, also inhibits the reduction of food intake induced by the systemic administration of cholecystokinin octapeptide (CCK-8) in food deprived rats. On the basis of an increase in the size of a brief test meal which followed an oral preload and treatment with a single dose of proglumide, it was suggested that a role for endogenous cholecystokinin in satiety had been demonstrated. We attempted to replicate this finding and could not under very similar experimental conditions. Subsequently, we tested whether other proglumide doses would antagonize the satiating effect of a larger oral preload on test meal intake. When these results were also found to be negative, we confirmed that proglumide (at several doses) significantly antagonized the reduction in food intake induced by exogenous CCK-8 under our conditions. Since proglumide antagonized the satiating effect of exogenous CCK-8, but did not increase food intake after oral preloads that were presumed to release endogenous CCK, we conclude that a reliable satiating effect of endogenous CCK remains to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3714531     DOI: 10.1016/0196-9781(86)90073-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

Authors:  J G Csernansky; S Glick; J Mellentin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin.

Authors:  G Hewson; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

3.  Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329.

Authors:  S J Cooper; C T Dourish; D J Barber
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.